Cargando…
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers. Results: There were 146 patients enrolled; common tumor types were colorectal, sarcoma, and ovari...
Autores principales: | Piha-Paul, Sarina A., Taylor, Matthew H., Spitz, Daniel, Schwartzberg, Lee, Beck, J. Thaddeus, Bauer, Todd M., Meric-Bernstam, Funda, Purkayastha, Das, Karpiak, Linda, Szpakowski, Sebastian, Braiteh, Fadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849647/ https://www.ncbi.nlm.nih.gov/pubmed/31741715 http://dx.doi.org/10.18632/oncotarget.27251 |
Ejemplares similares
-
Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018) -
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017) -
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020) -
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016) -
PI3K in T Cell Adhesion and Trafficking
por: Johansen, Kristoffer H., et al.
Publicado: (2021)